David A. Siegel Corbus Pharmaceuticals Holdings, Inc. Transaction History

Two Sigma Advisers, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.17 - $5.31 $2,856 - $89,208	16,800 New	16,800 $3,000
Q2 2022 Aug 15, 2022	SELL	$0.21 - $0.53 $2,940 - $7,420	-14,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.32 - $0.67 $864 - $1,809	2,700 Added 23.89%	14,000 $7,000
Q4 2021 Feb 14, 2022	BUY	$0.6 - $1.11 $6,780 - $12,543	11,300 New	11,300 $7,000
Q3 2021 Nov 15, 2021	SELL	$1.01 - $1.82 $40,400 - $72,800	-40,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.39 - $2.21 $317,754 - $505,206	-228,600 Reduced 85.11%	40,000 $73,000
Q1 2021 May 17, 2021	BUY	$1.27 - $3.42 $282,575 - $760,950	222,500 Added 482.65%	268,600 $529,000
Q4 2020 Feb 16, 2021	BUY	$0.94 - $1.89 $43,334 - $87,129	46,100 New	46,100 $58,000
Q3 2020 Nov 16, 2020	SELL	$1.5 - $9.38 $78,150 - $488,698	-52,100 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$4.79 - $8.39 $249,559 - $437,119	52,100 New	52,100 $437,000
Q1 2020 May 15, 2020	SELL	$3.44 - $7.21 $46,096 - $96,614	-13,400 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$4.29 - $5.64 $33,462 - $43,992	-7,800 Reduced 36.79%	13,400 $73,000
Q3 2019 Nov 14, 2019	BUY	$4.87 - $7.08 $103,244 - $150,096	21,200 New	21,200 $103,000

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.27B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.